<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>753</td>
<td>Highlights of This Issue</td>
<td></td>
</tr>
<tr>
<td>755</td>
<td>PREDICTIVE BIOMARKERS TO ANTI-VEGF THERAPY: PROGRESS TOWARD AN ELUSIVE GOAL</td>
<td>Rekha Gyanchandani and Seungwon Kim*</td>
</tr>
<tr>
<td>758</td>
<td>MOLECULAR PATHWAYS: MULTIMODAL CANCER-KILLING MECHANISMS EMPLOYED BY ONCOYTIC VESICULOVIRUSES</td>
<td>Douglas J. Mahoney and David F. Stojdl*</td>
</tr>
<tr>
<td>764</td>
<td>THE DEFINITION OF PRIMARY AND SECONDARY GLOBLASTOMA</td>
<td>Hiroko Ohgaki and Paul Kleihues*</td>
</tr>
<tr>
<td>773</td>
<td>LACTATE DEHYDROGENASE B IS REQUIRED FOR THE GROWTH OF KRAS-DEPENDENT LUNG ADENOCARCINOMAS</td>
<td>Mark L. McClelland, Adam S. Adler, Laura Deming, Ely Cosino, Leslie Lee, Elizabeth M. Blackwood, Margaret Solon, Janet Tao, Li Li, David Shames, Erica Jackson, William F. Forrest, and Ron Firestein</td>
</tr>
<tr>
<td>785</td>
<td>RECIPROCAL INTERACTIONS BETWEEN TUMOR-ASSOCIATED MACROPHAGES AND OSTEOPOPTIN/CD44 PROMOTE TUMORIGENICITY IN COLORECTAL CANCER</td>
<td>Guanhua Rao, Hongyi Wang, Baowei Li, Li Huang, Danfeng Xue, Xiaohui Wang, Haijing Jin, Jun Wang, Yushan Zhu, Youyoung Lu, Lei Du, and Quan Chen</td>
</tr>
<tr>
<td>821</td>
<td>INFLUENCE OF HUMAN OATP1B1, OATP1B3, AND OATP1A2 ON THE PHARMACOKINETICS OF METHOTREXATE AND PALITAXEL IN HUMANIZED TRANSGENIC MICE</td>
<td>Evita van de Steeg, Ania van Esch, Els Wagenaar, Kathryn E. Kenworthy, and Alfred H. Schinkel</td>
</tr>
<tr>
<td>833</td>
<td>BLOCKED AUTOPHAGY USING LYSOSOMOTROPIC AGENTS SENSITIZES RESISTANT PROSTATE TUMOR CELLS TO THE NOVEL AKT INHIBITOR AZD5363</td>
<td>Francois Lamoureux, Christian Thomas, Claire Crafter, Masafumi Kumatana, Fan Zhang, Barry R. Davies, Martin E. Geave, and Amina Zoubeidi</td>
</tr>
<tr>
<td>845</td>
<td>CASPASE-INDEPENDENT CELL DEATH IS INVOLVED IN THE NEGATIVE EFFECT OF EGF RECEPTOR INHIBITORS ON CISPLATIN IN NON–SMALL CELL LUNG CANCER CELLS</td>
<td>Hirohito Yagamuchi, Jennifer L. Hsu, Chun-Ta Chen, Ying-Nai Wang, Ming-Chuan Hsu, Shih-Shin Chang, Yi Du, How-Wen Ko, Roy Herbst, and Mien-Chie Hung</td>
</tr>
</tbody>
</table>

*See article, p. 929
Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity
Nilesh A. Patankar, Julia Pritchard, Mariska van Grinsven, Maryam Osooly, and Marcel B. Bally

First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
Andrew X. Zhu, Philip J. Gold, Anthony B. El-Khoueiry, Thomas A. Abrams, Hideo Morikawa, Norihisa Ohishi, Toshihiko Ohtomo, and Philip A. Philip

DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett’s Esophagus
Muhammad A. Alvi, Xinxue Liu, Maria O’Donovan, Richard Newton, Lorenz Wernisch, Nicholas R. Shannon, Kareem Shariff, Massimiliano di Pietro, Jacques J.G.H.M. Bergman, Krish Ragunath, and Rebecca C. Fitzgerald

The Immune Signature of CD8⁺CCR7⁺ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Malgorzata Czystowska, William Gooding, Miroslaw J. Szczepanski, Andres Lopez-Abaitero, Robert L. Ferris, Jonas T. Johnson, and Theresa L. Whiteside

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde, Adrian M. Jubh, Dafeng Chen, Nicole F. Li, Y. Gloria Meng, Coen Bernaards, Rebecca Elliott, Stefan J. Scherer, and Daniel S. Chen
See commentary, p.755

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon, Morris D. Groves, Patrick T. Wen, Louis Nabors, Tom Mikkelson, Steve Rosenfeld, Jeffrey Raizer, Jorge Barriuso, Roger E. McLendon, A. Benjamin Suttle, Bo Ma, C. Martin Curtis, Mohammed M. Dar, and Johann de Bono

Long-term Prospective Population PK Study in GIST Patients—Letter
Etienne Chatelut, Peggy Gandia, Verena Gotta, and Nicolas Widmer

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

LETTERS TO THE EDITOR
Long-term Prospective Population PK Study in GIST Patients—Response
Ron H.J. Mathijssen, Peter de Bruijn, Karel Eechoute, and Alex Sparreboom

Correction: Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Reda Z. Mahfouz, Ania Jankowska, Quteba Ebrahem, Xiaorong Gu, Valeria Visconte, Ali Tabarroski, Pramod Tese, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engelske, Mikkael A. Sekeres, Ramon Tiu, Jaroslav Maciejewski, Tomas Radiovoyevitch, and Yogen Saunthararajah

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE
Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Reda Z. Mahfouz, Ania Jankowska, Quteba Ebrahem, Xiaorong Gu, Valeria Visconte, Ali Tabarroski, Pramod Tese, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engelske, Mikkael A. Sekeres, Ramon Tiu, Jaroslav Maciejewski, Tomas Radiovoyevitch, and Yogen Saunthararajah

IMAGING, DIAGNOSIS, PROGNOSIS
The Immune Signature of CD8⁺CCR7⁺ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Malgorzata Czystowska, William Gooding, Miroslaw J. Szczepanski, Andres Lopez-Abaitero, Robert L. Ferris, Jonas T. Johnson, and Theresa L. Whiteside

CANCER THERAPY: CLINICAL
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon, Morris D. Groves, Patrick T. Wen, Louis Nabors, Tom Mikkelson, Steve Rosenfeld, Jeffrey Raizer, Jorge Barriuso, Roger E. McLendon, A. Benjamin Suttle, Bo Ma, C. Martin Curtis, Mohammed M. Dar, and Johann de Bono

LETTERS TO THE EDITOR
Long-term Prospective Population PK Study in GIST Patients—Response
Ron H.J. Mathijssen, Peter de Bruijn, Karel Eechoute, and Alex Sparreboom

CORRECTION
Correction: Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Reda Z. Mahfouz, Ania Jankowska, Quteba Ebrahem, Xiaorong Gu, Valeria Visconte, Ali Tabarroski, Pramod Tese, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engelske, Mikkael A. Sekeres, Ramon Tiu, Jaroslav Maciejewski, Tomas Radiovoyevitch, and Yogen Saunthararajah
ABOUT THE COVER

The image displays a human prostate cell line (PC-3) that has been stained with antibodies against the autophagy marker Light Chain 3 (LC3; green) after rapamycin treatment. During autophagy, LC3-I is converted to LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows for LC3 to become associated with autophagic vesicles, as shown by green puncta. Tumor cell nuclei are visualized by DAPI (blue). For details, see the article by Lamoureux and colleagues on page 833 of this issue.